Zyngenia Attracts NEA. 11/4/2009 Private Placement.
Thomson recorded this investment at only $3M. The press release clearly stated that it was the full $10M. Either amount falls below the normal threshold for the mighty NEA. More than likely, if this early stage investment in a Biotech company focused on cancer and autoimmune disorders works, then there will many more calls for capital. It warms the heart to see NEA takes chances and invest its fair share in companies in its home market. It would be a stretch to label NEA as an altruistic enterprise, but there is a long and rich history of partners supporting the local investment community as well as being proactive in investing in their backyard.